# Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

> **NCT01877668** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 422 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Tofacitinib 5 mg BID
- **DRUG:** Tofacitinib 10 mg BID
- **DRUG:** Adalimumab
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01877668
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-20
- **Primary completion:** 2015-12-18
- **Final completion:** 2015-12-18
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01877668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01877668, "Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01877668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*